Tag: Syngene International
Overstepping the mark
The requirement to submit a test licence in the drugs and cosmetics rules goes beyond the ambit of the Parent Act, and is a hindrance to R&D for pharma companies, writes Syngene International's Shreekanth Katti
LATEST ON LAW.ASIA
ANI v OpenAI ruling: Reading the tea leaves
In-house legal teams that adapt now will be better placed for the final judgment after the first ruling on AI training and copyright
